H1N1 pandemic influenza virus vaccine - Sinovac Biotech

Drug Profile

H1N1 pandemic influenza virus vaccine - Sinovac Biotech

Alternative Names: Influenza A (H1N1) vaccine - Sinovac Biotech; Panflu.1; Swine flu vaccine - Sinovac Biotech

Latest Information Update: 24 Mar 2015

Price : $50

At a glance

  • Originator Sinovac Biotech
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 30 Mar 2010 Preregistration for Influenza-A virus H1N1 subtype in India (IM)
  • 30 Mar 2010 H1N1 vaccine licensed to Parenteral Drugs Ltd in India
  • 17 Nov 2009 The State Food and Drug Administration approves Panflu.1 for use in elderly patients aged > 60 years for prevention of Influenza-A virus H1N1 subtype in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top